Near-infrared two-region chemiluminescence resonance energy transfer nano system as well as preparation method and application thereof
Through the microenvironment dual-response activation strategy of the near-infrared 2-zone chemiluminescence resonance energy transfer nanosystem, the rapid and accurate problems in the diagnosis of sentinel lymph nodes in breast cancer are solved, and the rapid and accurate diagnosis of sentinel lymph nodes in breast cancer is achieved, avoiding the traditional The false negative and false positive results in the method also improve the accuracy and sensitivity of the detection.
Patent Information
- Application Number
- CN202410948618.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-16
AI Technical Summary
The existing breast cancer sentinel lymph node diagnosis methods have problems such as difficulty in tissue extraction, high risk of metastasis and long-term pathological evaluation of the diagnosis results, making it difficult to achieve rapid and accurate diagnosis.
Using the near-infrared two-zone chemiluminescence resonance energy transfer nanosystem, the microenvironment dual-response activated nanosystem is constructed through the multi-component collaborative self-assembly of the pH-responsive amphiphilic short peptide, metal ions and NIR-II CRET system to realize the Rapid and accurate diagnosis of sentinel lymph nodes in breast cancer.
Accurate positioning and diagnosis of metastatic sentinel lymph nodes is achieved, false negative and false positive results are avoided, and the high tissue penetration and high spatiotemporal resolution of the NIR-II window are used to improve the accuracy and sensitivity of cancer detection.
Smart Images

Figure CN118914129A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of optical detection technology, and in particular to a near-infrared second-zone chemiluminescence resonance energy transfer nanosystem and a preparation method and application thereof. Background Art
[0002] Breast cancer is one of the most important public health issues that endanger women's health. Breast cancer metastasis is the main cause of clinical patient death. Therefore, early detection and effective intervention of breast cancer are key links to improve efficacy and improve patients' quality of life. Clinical studies have shown that breast cancer cells spread preferentially through lymphatic metastasis. Among them, sentinel lymph nodes are considered to be the first site to arrive after breast cancer cells spread. Therefore, the accurate identification of metastatic sentinel lymph nodes helps in the clinical classification and staging of breast cancer, and has important clinical significance for guiding patient treatment.
[0003] Sentinel lymph node biopsy for breast cancer is currently the most common method for sentinel lymph node diagnosis, which mainly includes dye tracer method, radioisotope labeling method represented by 99mTc, ultrasound angiography and fluorescence tracer method. The above methods have achieved accurate sentinel lymph node localization and benefited many patients, but they all require tissue sampling and pathological staining to identify sentinel lymph nodes. There are still some problems that cannot be ignored: first, it is difficult to obtain complete information on sentinel lymph node metastasis through partial tissue extraction; second, invasive tissue extraction increases the risk of metastasis; in addition, the identification results require a long pathological evaluation process. Therefore, how to achieve rapid and accurate diagnosis of sentinel lymph nodes in breast cancer is an urgent clinical need to be solved.
[0004] Fluorescence molecular imaging technology has a series of advantages such as high sensitivity, high specificity, intuitive visualization, green and convenient. Among them, near-infrared II (NIR-II, 1000-1700nm) imaging technology shows excellent tissue penetration, spatial resolution and low tissue autofluorescence, which significantly improves the accuracy and sensitivity of cancer diagnosis. The pathological characteristics of the tumor microenvironment have been used to develop various tumor tissue-activated nanofluorescent probes. However, a single detection indicator is difficult to ensure accurate results.
[0005] Studies have shown that tumor-associated macrophages (TAMs) and neutrophils (TANs) account for a significant proportion of metastatic breast cancer; among them, myeloperoxidase (MPO enzyme) is an important component of TAMs and TANs and is closely related to tumor metastasis. The specific recognition of MPO enzyme activity signals has become a new strategy for detecting metastatic lymph nodes.
[0006] In view of the problems existing in the above-mentioned prior art, the present invention provides a near-infrared two-zone CRET technology method based on microenvironment dual-response activation, and applies it to the localization of sentinel lymph nodes of breast cancer and the drug preparation for the integrated diagnosis and treatment of qualitative characteristics. Summary of the invention
[0007] In view of this, the present invention provides a technical problem to be solved by the present invention, namely, to provide a near-infrared second-zone chemiluminescence resonance energy transfer nanosystem and its preparation method and application, so as to realize rapid and accurate diagnosis and treatment of sentinel lymph nodes of breast cancer.
[0008] In order to achieve the above-mentioned object, the present invention provides a near-infrared II (NIR-II, 1000-1700nm) chemiluminescence resonance energy transfer nanosystem, which is constructed by multi-component collaborative self-assembly of a pH-responsive amphiphilic short peptide, a metal ion, a NIR-II CRET system and a photosensitizer; the near-infrared II chemiluminescence resonance energy transfer nanosystem has a dual-responsive activation function of pH and MPO enzyme in a microenvironment to enhance the NIR-II CRET signal.
[0009] Preferably, the pH-responsive amphiphilic short peptide is any one of N-fluorenylmethoxycarbonyl-L-histidine (Fmoc-His), N-fluorenylmethoxycarbonyl-L-lysine (Fmoc-Lys), N-fluorenylmethoxycarbonyl-L-arginine (Fmoc-Arg), N-fluorenylmethoxycarbonyl-L-cysteine (Fmoc-Cys), and any combination of two or more thereof.
[0010] Preferably, the metal ion is a gadolinium ion (Gd 3+ ), erbium ions (Er 3+ ), iron ions (Fe 3+ ), calcium ions (Ca 2 + ), copper ions (Cu 2+ ), magnesium ion (Mg 2+ ), zinc ion (Zn 2+ ), manganese ion (Mn 2+ ) or any combination of two or more.
[0011] Preferably, the NIR-II CRET system comprises a near-infrared II contrast agent and a compound having chemiluminescence ability.
[0012] More preferably, the compound having chemiluminescent ability is luminol or a luminol derivative; the luminol derivative is selected from 4-aminohexyl-N-ethylisoluminol (ABEI) and / or ethylluminol (AHEI).
[0013] Preferably, the near-infrared zone II contrast agent at least includes near-infrared quantum dots.
[0014] Preferably, the near-infrared quantum dots are near-infrared quantum dots modified with one or any combination of two or more of mercaptopropionic acid, undecanoic acid, glutathione, and lipoic acid.
[0015] More preferably, the near-infrared quantum dots are Ag 2 S, Ag 2 Se, AgTe, Au:Ag 2 One of Te, AgAuSe or any combination of two or more.
[0016] Preferably, the photosensitizer is one or any combination of two or more of dihydrochlorin e6 (Ce6), benzoporphyrin derivative (BPD), 2-(1-hexaoxyethyl)-2-devinyl pyrophosphate (HPPH), and benzoporphyrin monocyclic acid A (BPD-MA).
[0017] As another object, the present invention also provides a method for preparing the above-mentioned near-infrared second-zone chemiluminescence resonance energy transfer nanosystem, comprising mixing a pH-responsive amphiphilic short peptide, a metal ion, a NIR-II CRET system and a photosensitizer and then conducting multi-component collaborative self-assembly to prepare a near-infrared second-zone chemiluminescence resonance energy transfer nanosystem; the multi-component collaborative self-assembly includes electrostatic adsorption, metal coordination, hydrophobic interaction, and π-π stacking interaction between the pH-responsive amphiphilic short peptide, the metal ion, the NIR-II CRET system and the photosensitizer.
[0018] Specifically, the preparation method comprises the following steps:
[0019] (1) Provide NIR-II CRET system solution;
[0020] The method for preparing the NIR-II CRET system is characterized in that the NIR-II CRET system solution is obtained by dissolving a near infrared II contrast agent and a chemiluminescent compound in water respectively to obtain a contrast agent solution and a chemiluminescent compound solution; the contrast agent solution and the chemiluminescent compound solution are mixed, and the mixture is continuously stirred for 30 to 120 minutes and then purified to obtain the NIR-II CRET system solution;
[0021] (2) providing an amphiphilic short peptide solution, a metal ion solution, and a photosensitizer solution;
[0022] Dissolving the pH-responsive amphiphilic short peptide in water to obtain the amphiphilic short peptide solution;
[0023] dissolving metal ions in water to obtain the metal ion solution;
[0024] Dissolving a photosensitizer in an organic solvent to obtain the photosensitizer solution;
[0025] (3) Preparation of NIR-II CRET nanosystem;
[0026] The NIR-II CRET system solution purified in step (1) is mixed with the amphiphilic short peptide solution and the metal ion solution in step (2), and stirred continuously for 10 to 40 minutes; then, the photosensitizer solution prepared in step (2) is added, mixed evenly, the pH is adjusted to neutral, purified, and concentrated to obtain the NIR-II CRET nanosystem.
[0027] Preferably, in step (1) and step (4), the purification is ultrafiltration purification.
[0028] Preferably, the method for preparing the chemiluminescent compound solution comprises dissolving the chemiluminescent compound in an alkaline solution; the pH of the alkaline solution is 8.0-9.0.
[0029] Preferably, the mass ratio of the near-infrared second zone contrast agent to the chemiluminescent compound is in the range of 1-10:0.1-1.
[0030] Preferably, in step (2), the organic solvent is dimethyl sulfoxide.
[0031] Preferably, the concentration of the amphiphilic short peptide solution is 1-5 mg / mL.
[0032] Preferably, the concentration of the metal ion solution is 5 to 20 mmol / mL.
[0033] Preferably, the concentration of the photosensitizer solution is 1-10 mg / mL.
[0034] Preferably, in step (3), the mass addition ratio of the near-infrared zone II contrast agent, the chemiluminescent compound, the amphiphilic short peptide, the metal ion and the photosensitizer in the near-infrared zone II CRET nanosystem is 1-10:50-100:5-50:50-200:1-5.
[0035] The pH value of the near-infrared second-zone chemiluminescence resonance energy transfer nanosystem is neutral; under neutral conditions, the average size of the NIR-II CRET nanosystem is 20 to 500 nm.
[0036] Based on the above technical scheme, the present invention obtains a near-infrared second-zone chemiluminescence resonance energy transfer nanosystem by mixing pH-responsive amphiphilic short peptides, metal ions, NIR-II CRET system and photosensitizer through multi-component collaborative self-assembly. The multi-component collaborative self-assembly includes electrostatic adsorption, metal coordination, hydrophobic interaction and π-π stacking interaction between pH-responsive amphiphilic short peptides, metal ions, NIR-II CRET system and photosensitizer. The system is used as a diagnostic reagent to establish a universal breast cancer sentinel lymph node localization and qualitative integrated diagnosis and treatment technology, which provides a new method for the application of near-infrared second-zone contrast agents and CRET optical systems in clinical breast cancer sentinel lymph node diagnosis and treatment.
[0037] Beneficial technical effects obtained by the present invention:
[0038] (1) The present invention integrates dual-mode optics and pH / MPO synergistic activation strategies to achieve precise localization and diagnosis of metastatic sentinel lymph nodes, effectively avoiding "false negative" and "false positive" results.
[0039] (2) Benefiting from the high tissue penetration, high spatiotemporal resolution, and high signal-to-noise ratio imaging characteristics in the NIR-II window, the use of this technical invention scheme facilitates the detection of deeper and earlier metastatic lesions. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 It is a transmission electron micrograph of the microenvironment dual-responsive activated NIR-II CRET nanosystem prepared in Example 1 of the present invention under different pH environments.
[0041] Figure 2 It is a transmission electron micrograph of the microenvironment dual-responsive activated NIR-II CRET nanosystem prepared in Example 2 of the present invention under different pH environments.
[0042] Figure 3a and Figure 3b They are respectively the CRET spectrum and the fluorescence quantitative curve generated by the NIR-II CRET nanosystem of Example 2 of the present invention through the MPO enzyme catalytic reaction in vitro.
[0043] Figure 4 This is a diagram showing the effect of using the microenvironment dual-response activated NIR-II CRET nanosystem prepared in Example 1 of the present invention for in vivo breast cancer sentinel lymph node detection.
[0044] Figure 5 These are the immunofluorescence staining and hematoxylin-eosin (H&E) staining effects of metastatic sentinel lymph node tissue and negative sentinel lymph node tissue removed under the guidance of CRET signaling. DETAILED DESCRIPTION
[0045] In order to make the purpose, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below in combination with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments.
[0046] The present invention provides a microenvironment dual-response activated NIR-II CRET nanosystem, the nanosystem comprising pH-responsive amphiphilic short peptides, metal ions, a CRET system and a photosensitizer. The nanosystem is prepared by synergistic self-assembly such as electrostatic adsorption, metal coordination, hydrophobic interaction, π-π stacking and the like among the above-mentioned multiple components.
[0047] The present invention combines the optical properties of high tissue penetration and high spatiotemporal resolution of near-infrared zone II imaging technology with the pathological characteristics of the breast cancer tumor microenvironment, and prepares a microenvironment dual-response activated NIR-II CRET nanosystem through a multi-component collaborative self-assembly process. The nanosystem can realize the positioning of sentinel lymph nodes through near-infrared fluorescence signals, and the qualitative characterization of sentinel lymph nodes through NIR-II CRET signals programmed with pH and MPO enzyme activation, overcoming the difficulty of traditional methods in achieving integrated in vivo positioning and qualitative characterization, and providing a new method for the precise diagnosis and treatment of sentinel lymph nodes in breast cancer.
[0048] In some specific embodiments, the pH-responsive amphiphilic short peptide is any one of N-fluorenylmethoxycarbonyl-L-histidine (Fmoc-His), N-fluorenylmethoxycarbonyl-L-lysine (Fmoc-Lys), N-fluorenylmethoxycarbonyl-L-arginine (Fmoc-Arg), N-fluorenylmethoxycarbonyl-L-cysteine (Fmoc-Cys) and any combination thereof.
[0049] In some specific embodiments, the metal ion is a gadolinium ion (Gd 3+ ), erbium ions (Er 3+ ), iron ions (Fe 3 + ), zinc ion (Zn 2+ ) or any combination thereof.
[0050] In some specific embodiments, the NIR-II CRET system is loaded with any combination of a near-infrared II contrast agent and a compound having chemiluminescence ability.
[0051] In some specific embodiments, the photosensitizer is one of dihydrochlorin e6 (Ce6), benzoporphyrin derivative (BPD), 2-(1-hexaoxyethyl)-2-devinyl pyrophosphate (HPPH), benzoporphyrin monocyclic acid A (BPD-MA) or any combination thereof.
[0052] In some specific embodiments, the nanosystem, CRET system and NIR-II contrast agent include near-infrared quantum dots.
[0053] In some specific embodiments, the near-infrared quantum dots are Ag 2 S, Ag 2 Se, AgTe, Au:Ag 2 Te, AgAuSe or any combination thereof.
[0054] In some specific embodiments, the near-infrared quantum dots are near-infrared quantum dots modified with one of mercaptopropionic acid, undecanoic acid, glutathione, lipoic acid, or any combination thereof.
[0055] In some specific embodiments, the compound having chemiluminescent ability is luminol or its derivatives 4-aminohexyl-N-ethylisoluminol (ABEI), ethyl luminol (AHEI), one of them, and any combination thereof.
[0056] On the other hand, the present invention provides a method for preparing the microenvironment dual-response activated NIR-II CRET nanosystem as described above, characterized in that the preparation method comprises the following steps:
[0057] (1) dissolving a near-infrared II contrast agent and a chemiluminescent compound in water respectively to obtain two solutions;
[0058] (2) The two solutions obtained in (1) were mixed and stirred for one hour, and then purified to remove excess chemiluminescent compounds.
[0059] (3) The amphiphilic short peptide and the metal ion are dissolved in water respectively, the photosensitizer is dissolved in an organic solvent, and a photosensitizer solution is obtained by ultrasound.
[0060] (4) The purified CRET system solution obtained in (2) and the amphiphilic short peptide solution in (3) are mixed with the metal ion solution in (3) at the same time, and stirred for 30 minutes, and then the photosensitizer solution in (3) is added, and the pH of the mixed solution is adjusted to neutral and purified and concentrated to obtain the pH and MPO enzyme dual-responsive activated NIR-II CRET nanosystem.
[0061] The present invention provides an application of a microenvironment dual-response activated NIR-II CRET nanosystem in sentinel lymph node localization and qualitative integrated diagnosis and treatment of breast cancer.
[0062] It should be noted that, unless otherwise specified, the raw materials and chemical reagents used in the present invention are all commercially available.
[0063] The technical solutions in the embodiments of the present invention are clearly and completely described below through specific embodiments and drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0064] Example 1
[0065] This embodiment provides a method for preparing a NIR-II CRET nanosystem based on microenvironment dual-response activation, and the specific steps include:
[0066] (1) dissolving 10 mg of 4-(N-ethyl-N-aminobutylamino)phthalhydrazide (ABEI), 0.5 g of sodium bicarbonate and 200 μL of concentrated aqueous ammonia in water to obtain an ABEI solution;
[0067] (2) 1 mg of undecanoic acid-modified Ag 2 S quantum dots were dissolved in water to obtain an aqueous quantum dot solution (average concentration of 0.5 mg / mL);
[0068] (3) mixing the ABEI solution obtained in (1) and the quantum dot solution obtained in (2) at a mass ratio of 100:1, and stirring for 1 hour at a stirring speed of 300 rpm;
[0069] (4) the solution obtained in (3) was purified by ultrafiltration three times, each time for 10 minutes, to remove excess ABEI, thereby obtaining a purified CRET system solution;
[0070] (5) 1 mg of fluorenylmethoxycarbonyllysine (Fmoc-Lys), 5 mmol of ErCl 3 Dissolve them in 1 mL of water to obtain Fmoc-Lys solution and ErCl 3 Solution: 1 mg of phenylphosphonium dichloride (BPD) was dissolved in 1 mL of DMSO to obtain a BPD solution.
[0071] (6) The NIR-II CRET system solution obtained in step (4) and the Fmoc-Lys solution obtained in step (5) are simultaneously reacted with ErCl 3The solutions were mixed and stirred for 30 minutes at a stirring speed of 300 rpm to obtain a mixed solution;
[0072] (7) The BPD solution prepared in step (5) and the mixed solution prepared in step (6) were evenly mixed, and the solution was divided into two parts, and the pH was adjusted to pH = 7.4 and pH = 5.5 respectively. After continuous stirring for 1 hour, ultrafiltration and concentration were performed to obtain a purified NIR-II CRET nanosystem.
[0073] like Figure 1 As shown, it is a morphological characterization diagram of the NIR-II CRET nanosystem provided in this embodiment. From the transmission electron microscopy image, it can be seen that the size of the nanosystem is about 120nm under pH 7.4 conditions, and the size of the nanosystem is about 30nm under pH 5.5 environment; indicating that the NIR-II CRET nanosystem is successfully prepared in a pH 7.4 environment and depolymerized in a pH 5.5 environment.
[0074] Example 2
[0075] This embodiment provides a method for preparing a NIR-II CRET nanosystem based on microenvironment dual-response activation, and the specific steps include:
[0076] (1) Dissolve 20 mg of luminol, 1 g of sodium bicarbonate, and 100 μL of concentrated aqueous ammonia in water to obtain a 10 mM luminol solution;
[0077] (2) dissolving 1 mg of mercaptopropionic acid-modified AgAuSe quantum dots in water to obtain a 2 mg / mL quantum dot solution;
[0078] (3) mixing the luminol solution obtained in step (1) with the quantum dot solution obtained in step (2) (at an average mass ratio of 50:1), and stirring for 1 hour at a stirring speed of 300 rpm;
[0079] (4) The solution obtained in step (3) was purified by ultrafiltration three times, each time for 10 minutes, to remove excess luminol and obtain a purified NIR-II CRET system solution.
[0080] (5) 1 mg of fluorenylmethoxycarbonylhistidine (Fmoc-His), 2 mmol of GdCl 3 Dissolve in 1 mL of water to obtain Fmoc-His solution and GdCl 3 The solution was prepared by dissolving 2 mg of dihydrochlorin e6 (Ce6) in 1 mL of DMSO.
[0081] (6) The NIR-II CRET solution obtained in step (4) and the Fmoc-His solution obtained in step (5) are simultaneously reacted with GdCl3 The solutions were mixed and stirred for 30 min at a stirring speed of 300 rpm;
[0082] (7) After mixing all the Ce6 solutions obtained in step (5) with all the mixed solutions in step (6), the solutions were divided into two and the pH values were adjusted to pH = 7.4 and pH = 5.5, respectively. After continuous stirring for 1 hour, the solutions were concentrated by ultrafiltration to obtain a purified NIR-II CRET nanosystem.
[0083] like Figure 2 As shown, it is a morphological characterization diagram of the NIR-II CRET nanosystem provided in this embodiment. The characterization of the transmission electron microscopy image shows that the size of the nanosystem is about 80nm under pH 7.4 conditions, and the size of the nanosystem is about 27nm under pH 5.5 conditions; further, it can be seen from the figure that the NIR-II CRET nanosystem is successfully prepared in a pH 7.4 environment and depolymerizes in a pH 5.5 environment.
[0084] like Figure 3a and Figure 3b As shown in FIG. 1 , the CRET spectrum and fluorescence quantitative curve generated by the NIR-II CRET nanosystem of this embodiment in vitro through the MPO enzyme catalysis reaction. Figure 3a It can be seen that CRET signals can be generated in vitro through MPO enzyme catalysis reaction; see Figure 3b The quantitative curve of the change of CRET signal with time under different pH environments (CRET signal-time quantitative curve) showed that pH 5.5 could produce a stronger CRET signal than pH 7.4, proving that the nanosystem has a significant pH-dependent MPO enzyme response function.
[0085] Example 3
[0086] The NIR-II CRET nanosystem obtained in Example 2 of the present invention is selected as a diagnostic agent for in vivo evaluation / diagnosis of breast cancer metastatic sentinel lymph nodes, and the specific steps include:
[0087] (1) A breast cancer lymph node metastasis mouse model was constructed, and the optimal dose of the nanosystem solution was subcutaneously injected into the model mice and normal mice via the mouse paw pad; the mice were imaged in real time using a near-infrared in vivo imager; the changes in the sentinel lymph node fluorescence signals of the two groups of mice were observed and real-time fluorescence images were collected. After imaging, the sentinel lymph node tissues of the mice were collected for histopathological staining analysis.
[0088] (2) Postoperative histopathological staining analysis: The lymph node tissue sections removed above were subjected to immunofluorescence staining and H&E staining. An inverted fluorescence microscope was used to collect images of the stained sections and perform pathological analysis. The above in vivo fluorescence images and histopathological staining results were compared to analyze the consistency of the near-infrared fluorescence signals, NIR-II CRET signals and histopathological diagnosis of metastatic lymph nodes and normal lymph nodes.
[0089] The analysis methods in the above steps are all conventional technical means commonly used in the prior art.
[0090] like Figure 4 As shown, under 808nm laser irradiation, the nanosystem can accurately locate the sentinel lymph nodes of breast cancer. In the absence of laser, the nanosystem successfully identified the metastatic sentinel lymph nodes through the NIR-II CRET signal, while no obvious NIR-II CRET signal was observed in the negative sentinel lymph nodes. This indicates that the metastatic sentinel lymph nodes can be accurately detected by the NIR-IICRET signal under the dual response activation of pH and MPO enzyme.
[0091] like Figure 5 As shown, the tissue-level H&E staining results of the metastatic sentinel lymph nodes indicated the results of TAM and TAN infiltrating tumor cells, and the immunofluorescence staining images showed that the MPO enzyme was highly expressed. The results showed that the nanosystem achieved the qualitative analysis of the metastatic sentinel lymph nodes through the CRET signal generated by MPO enzyme catalysis.
[0092] Therefore, the above results indicate that the near-infrared II chemiluminescence resonance energy transfer nanosystem provided by the technical solution of the present invention can be used as a diagnostic and therapeutic reagent for sentinel lymph nodes of breast cancer, has pH dependence and MPO enzyme response function, undergoes depolymerization reaction under acidic conditions, and can enhance the NIR-II CRET signal, thereby realizing the localization and qualitative integrated diagnosis and treatment of sentinel lymph nodes of breast cancer at the in vivo level.
[0093] The various aspects, embodiments, features and examples of the present invention should be considered as illustrative in all aspects and are not intended to limit the present invention, the scope of the present invention is defined only by the claims. Other embodiments, modifications and uses will be apparent to those skilled in the art without departing from the spirit and scope of the claimed invention.
[0094] The use of headings and descriptions in the context of the present invention is not meant to limit the invention; each section may apply to any aspect, embodiment or feature of the invention.
[0095] Throughout the present disclosure, where a composition is described as having, comprising, or including particular components, or where a process is described as having, comprising, or including particular process steps, it is contemplated that the compositions taught by the present invention also consist essentially of, or consist of, the recited components, and that the processes taught by the present invention also consist essentially of, or consist of, the recited process steps.
[0096] Unless specifically stated otherwise, use of the terms "include," "includes," "including," "have," "has," or "having" should generally be construed as open ended and non-limiting.
[0097] It should be understood that the order of the various steps or the order in which a particular action is performed is not very important, as long as the teachings of the present invention remain operable. In addition, two or more steps or actions may be performed simultaneously.
[0098] In addition, the inventors of this case also referred to the aforementioned embodiments and conducted experiments with other raw materials, process operations, and process conditions described in this specification, and obtained relatively ideal results.
[0099] Although the present invention has been described with reference to illustrative embodiments, it will be appreciated by those skilled in the art that various other changes, omissions and / or additions may be made without departing from the spirit and scope of the present invention and that the elements of the embodiments may be replaced by substantial equivalents. In addition, many modifications may be made without departing from the scope of the present invention to adapt specific circumstances or materials to the teachings of the present invention. Therefore, it is not intended herein to limit the present invention to the disclosed specific embodiments for performing the present invention, but it is intended that the present invention will include all embodiments within the scope of the appended claims. In addition, unless specifically stated, any use of the terms first, second, etc. does not indicate any order or importance, but rather uses the terms first, second, etc. to distinguish one element from another.
Claims
1. A near-infrared second-region chemiluminescence resonance energy transfer nanosystem, characterized in that: It is constructed by multi-component collaborative self-assembly of pH-responsive amphiphilic short peptides, metal ions, NIR-IICRET system and photosensitizer; The near-infrared second-zone chemiluminescence resonance energy transfer nanosystem has a NIR-IICRET signal that is activated by dual response to pH and MPO enzyme in a microenvironment.
2. The near-infrared second-region chemiluminescence resonance energy transfer nanosystem according to claim 1, characterized in that: The pH-responsive amphiphilic short peptide is any one of N-fluorenylmethoxycarbonyl-L-histidine (Fmoc-His), N-fluorenylmethoxycarbonyl-L-lysine (Fmoc-Lys), N-fluorenylmethoxycarbonyl-L-arginine (Fmoc-Arg), and N-fluorenylmethoxycarbonyl-L-cysteine (Fmoc-Cys), and any combination of two or more thereof.
3. The near-infrared second-region chemiluminescence resonance energy transfer nanosystem according to claim 1, characterized in that: The metal ion is a gadolinium ion (Gd 3+ ), erbium ions (Er 3+ ), iron ions (Fe 3+ ), calcium ions (Ca 2+ ), copper ions (Cu 2+ ), magnesium ion (Mg 2+ ), zinc ion (Zn 2+ ), manganese ion (Mn 2+ ) or any combination of two or more.
4. The near-infrared second-region chemiluminescence resonance energy transfer nanosystem according to claim 1, characterized in that: The CRET system comprises a near-infrared zone II contrast agent and a compound having chemiluminescence ability; The compound having chemiluminescence ability is luminol or a luminol derivative; the luminol derivative is selected from 4-aminohexyl-N-ethyl isoluminol (ABEI) and / or ethyl luminol (AHEI); And / or, the near-infrared zone II contrast agent comprises at least one of the contrast agents including near-infrared quantum dots; Preferably, the near-infrared quantum dots are near-infrared quantum dots modified with one or any combination of two or more of mercaptopropionic acid, undecanoic acid, glutathione, and lipoic acid; Preferably, the near-infrared quantum dots are one or any combination of two or more of Ag2S, Ag2Se, AgTe, Au:Ag2Te, AgAuSe.
5. The near-infrared second-region chemiluminescence resonance energy transfer nanosystem according to claim 1, characterized in that: The photosensitizer is one or any combination of two or more of dihydrochlorin e6 (Ce6), benzoporphyrin derivative (BPD), 2-(1-hexaoxyethyl)-2-devinyl pyrophosphate (HPPH), and benzoporphyrin monocyclic acid A (BPD-MA).
6. A method for preparing the near-infrared second-region chemiluminescence resonance energy transfer nanosystem according to any one of claims 1 to 5, characterized in that: The pH-responsive amphiphilic short peptide, metal ions, NIR-IICRET system and photosensitizer were mixed and then subjected to multi-component collaborative self-assembly to prepare the near-infrared II chemiluminescence resonance energy transfer nanosystem. The multi-component collaborative self-assembly includes electrostatic adsorption, metal coordination, hydrophobic interaction, and π-π stacking between pH-responsive amphiphilic short peptides, metal ions, a NIR-IICRET system, and a photosensitizer.
7. The preparation method according to claim 6, characterized in that: The following steps are involved: (1) Providing NIR-IICRET system solution; Dissolving a near-infrared second-zone contrast agent and a chemiluminescent compound in water respectively to obtain a contrast agent solution and a chemiluminescent compound solution; mixing the contrast agent solution and the chemiluminescent compound solution, stirring for 30 to 120 minutes, and then purifying to obtain the CRET system solution; (2) providing an amphiphilic short peptide solution, a metal ion solution, and a photosensitizer solution; Dissolving the pH-responsive amphiphilic short peptide in water to obtain the amphiphilic short peptide solution; dissolving metal ions in water to obtain the metal ion solution; Dissolving a photosensitizer in an organic solvent to obtain the photosensitizer solution; (3) Preparation of NIR-IICRET nanosystem; The CRET system solution purified in step (1) is mixed with the amphiphilic short peptide solution and the metal ion solution in step (2), and stirred continuously for 10 to 40 minutes; then, the photosensitizer solution prepared in step (2) is added, mixed evenly, the pH is adjusted to neutral, and the NIR-IICRET nanosystem is obtained after purification and concentration.
8. The preparation method according to claim 7, characterized in that: In step (1) and step (4), the purification is ultrafiltration purification; The method for preparing the chemiluminescent compound solution comprises dissolving the chemiluminescent compound in an alkaline solution; The pH of the alkaline solution is 8.0 to 9.0; The mass ratio of the near-infrared second-zone contrast agent to the chemiluminescent compound is 1-10:0.1-1; In step (2), the organic solvent is dimethyl sulfoxide; The concentration of the amphiphilic short peptide solution is 1 to 5 mg / mL; The concentration of the metal ion solution is 5 to 20 mmol / mL; The concentration of the photosensitizer solution is 1 to 10 mg / mL; In step (3), the mass addition ratio of the near-infrared zone II contrast agent, the chemiluminescent compound, the amphiphilic short peptide, the metal ion and the photosensitizer in the NIR-IICRET nanosystem is 1-10:50-100:5-50:50-200:1-5. The near-infrared second-zone chemiluminescence resonance energy transfer nanosystem is under neutral conditions, and the average size of the NIR-IICRET nanosystem is 20 to 500 nm.
9. Use of the near-infrared second-zone chemiluminescence resonance energy transfer nanosystem as described in any one of claims 1 to 6 in the preparation of a diagnostic and therapeutic agent for sentinel lymph nodes of breast cancer.
10. A diagnostic and therapeutic reagent for sentinel lymph nodes of breast cancer, comprising at least the near-infrared second-zone chemiluminescence resonance energy transfer nanosystem as described in any one of claims 1 to 6, wherein the diagnostic reagent has pH dependence and MPO enzyme response function, undergoes depolymerization reaction under acidic conditions, and can enhance the NIR-IICRET signal.
Citation Information
Patent Citations
Method for preparing pH-responsive histidine short peptide-metal coordination polymer nanoparticles
CN109771390A
Near-Infrared-II Nanoparticles and Related Compositions and Methods
US20220145175A1
Cited By
Near-infrared-ii chemiluminescence resonance energy transfer nanosystem, preparation method therefor, and use thereof
EP4764455A1
Near-infrared-ii chemiluminescence resonance energy transfer nanosystem, preparation method therefor, and use thereof
WO2026016334A1
